Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Aug;3(8):e361-e387.
doi: 10.1016/S2352-3018(16)30087-X. Epub 2016 Jul 19.

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015

Collaborators

Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015

GBD 2015 HIV Collaborators. Lancet HIV. 2016 Aug.

Erratum in

  • Correction to Lancet HIV 2016; 3: e361-87.
    [No authors listed] [No authors listed] Lancet HIV. 2016 Sep;3(9):e408. doi: 10.1016/S2352-3018(16)30125-4. Epub 2016 Aug 22. Lancet HIV. 2016. PMID: 27562740 Free PMC article. No abstract available.

Abstract

Background: Timely assessment of the burden of HIV/AIDS is essential for policy setting and programme evaluation. In this report from the Global Burden of Disease Study 2015 (GBD 2015), we provide national estimates of levels and trends of HIV/AIDS incidence, prevalence, coverage of antiretroviral therapy (ART), and mortality for 195 countries and territories from 1980 to 2015.

Methods: For countries without high-quality vital registration data, we estimated prevalence and incidence with data from antenatal care clinics and population-based seroprevalence surveys, and with assumptions by age and sex on initial CD4 distribution at infection, CD4 progression rates (probability of progression from higher to lower CD4 cell-count category), on and off antiretroviral therapy (ART) mortality, and mortality from all other causes. Our estimation strategy links the GBD 2015 assessment of all-cause mortality and estimation of incidence and prevalence so that for each draw from the uncertainty distribution all assumptions used in each step are internally consistent. We estimated incidence, prevalence, and death with GBD versions of the Estimation and Projection Package (EPP) and Spectrum software originally developed by the Joint United Nations Programme on HIV/AIDS (UNAIDS). We used an open-source version of EPP and recoded Spectrum for speed, and used updated assumptions from systematic reviews of the literature and GBD demographic data. For countries with high-quality vital registration data, we developed the cohort incidence bias adjustment model to estimate HIV incidence and prevalence largely from the number of deaths caused by HIV recorded in cause-of-death statistics. We corrected these statistics for garbage coding and HIV misclassification.

Findings: Global HIV incidence reached its peak in 1997, at 3·3 million new infections (95% uncertainty interval [UI] 3·1-3·4 million). Annual incidence has stayed relatively constant at about 2·6 million per year (range 2·5-2·8 million) since 2005, after a period of fast decline between 1997 and 2005. The number of people living with HIV/AIDS has been steadily increasing and reached 38·8 million (95% UI 37·6-40·4 million) in 2015. At the same time, HIV/AIDS mortality has been declining at a steady pace, from a peak of 1·8 million deaths (95% UI 1·7-1·9 million) in 2005, to 1·2 million deaths (1·1-1·3 million) in 2015. We recorded substantial heterogeneity in the levels and trends of HIV/AIDS across countries. Although many countries have experienced decreases in HIV/AIDS mortality and in annual new infections, other countries have had slowdowns or increases in rates of change in annual new infections.

Interpretation: Scale-up of ART and prevention of mother-to-child transmission has been one of the great successes of global health in the past two decades. However, in the past decade, progress in reducing new infections has been slow, development assistance for health devoted to HIV has stagnated, and resources for health in low-income countries have grown slowly. Achievement of the new ambitious goals for HIV enshrined in Sustainable Development Goal 3 and the 90-90-90 UNAIDS targets will be challenging, and will need continued efforts from governments and international agencies in the next 15 years to end AIDS by 2030.

Funding: Bill & Melinda Gates Foundation, and National Institute of Mental Health and National Institute on Aging, National Institutes of Health.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Evolution of the HIV epidemic from 1980 to 2015 Global estimates of new HIV infections (A), people living with HIV/AIDS (B), HIV/AIDS deaths (C), and proportion of people living with HIV receiving ART (D). Shaded areas show 95% uncertainty intervals. ART=antiretroviral therapy.
Figure 2
Figure 2
Incidence of new HIV infections from 1980 to 2015, and HIV incidence in 2015 Global number of new HIV infections by region (A). Bars show the mean number of estimated new infections within a given year. Error bars represent 95% uncertainty intervals. Each Global Burden of Disease region is represented by a separate colour. HIV incidence by country (B). We calculated incidence as cumulative new cases of HIV throughout the year divided by the total population at the mid-year. Rates are per 100 000 people. Colour bins correspond to the 0–50th, 50–70th, 70–80th, 80–90th, 90th–92nd, 92nd–94th, 96–98th, 98–99th, and 99–100th percentiles to highlight variation within sub-Saharan Africa. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.
Figure 3
Figure 3
Number of people living with HIV receiving ART from 1995 to 2015, and the proportion living with HIV receiving ART in 2015 Number of people living with HIV receiving ART by region (A). Bars represent the mean number of people living with HIV who received ART within a given year. Error bars represent 95% uncertainty intervals. Each Global Burden of Disease (GBD) region is represented by a separate colour. Proportion of people living with HIV receiving ART by country (B). The number of people living with HIV receiving ART and the total number of people living with HIV are year-end point prevalences. ART=antiretroviral therapy. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.
Figure 4
Figure 4
Global HIV/AIDS deaths, 2005–15 Global deaths caused by HIV/AIDS resulting in either mycobacterial infection (tuberculosis) or other diseases, by age and sex in 2015 (A); dark shading indicates deaths caused by tuberculosis associated with HIV; light shading indicates deaths caused by other diseases resulting from HIV; error bars show 95% uncertainty intervals. Mean estimates of global and super-regional HIV/AIDS deaths per prevalent case fom 2005 to 2015 (B).
Figure 5
Figure 5
Comparison of GBD 2015 and UNAIDS 2014 estimates Adult HIV prevalence rate (A) and estimates of death caused by HIV/AIDS (B). UNAIDS' published prevalence values are limited to three decimal places. The x and y values of each point are the log transformation of the mean estimates from UNAIDS and GBD, respectively, enabling variation to be seen despite disparate values. Tick-mark labels on the x and y axes are the value of the mean estimate before log transformation (ie, the real value and not the log-transformed value is shown). Locations mentioned in the manuscript are highlighted by plotting the ISO 3 code of the location. Each location is plotted with a different colour by super-region. GBD=Global Burden of Disease. UNAIDS=the Joint United Nations Programme on HIV and AIDS. ZAF=South Africa. KEN=Kenya. NGA=Nigeria. COG=Democratic Republic of the Congo. SLE=Sierra Leone. BDI=Burkina Faso. COD=Congo. SEN=Senegal. SWZ=Swaziland.

Comment in

References

    1. Murray CJL, Ortblad KF, Guinovart C. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:1005–1070. - PMC - PubMed
    1. Ortblad KF, Lozano R, Murray CJL. The burden of HIV: insights from the Global Burden of Disease Study 2010. AIDS Lond Engl. 2013;27:2003–2017. - PMC - PubMed
    1. Naghavi M, Wang H, Lozano R. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385:117–171. - PMC - PubMed
    1. Murray CJL, Barber RM, Foreman KJ. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. Lancet. 2015;386:2145–2191. - PMC - PubMed
    1. Vos T, Barber RM, Bell B. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. - PMC - PubMed

Publication types